acoltremon
Trade name: Tryptyr
Small moleculeapproved
Approved
May 28, 2025
Clinical trial activity
4 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
3
Earliest trial started Apr 3, 2017 (NCT03162094)
Timeline
Indications
Approved for
Mechanism of action
TRPM8 agonist
Approval history
- approvedMay 28, 2025
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(NC(=O)[C@@H]2C[C@H](C)CC[C@H]2C(C)C)cc1- Mol. weight
- 289.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2441929 ↗
Also known as
- avx012
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07267481 | Phase 4 | Dec 15, 2025 | University of Alabama, Birmingham |
| NCT07281950 | Phase 4 | Dec 15, 2025 | Center for Sight |
| NCT07267299 | Phase 4 | Dec 1, 2025 | University of Alabama, Birmingham |
| NCT03162094 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2017 | AVX Pharma |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Alabama, Birmingham | Academic/Hospital | 2 | 2 | 1 | 2025 |
| AVX Pharma | For profit | 1 | 1 | 1 | 2017 |
| Center for Sight | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Alcon | For profit | MKTG | May 28, 2025 |